Endologix, Inc. (ELGX) Receives $3.83 Consensus Price Target from Brokerages

Endologix, Inc. (NASDAQ:ELGX) has received an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $3.83.

Several equities research analysts recently issued reports on the company. Zacks Investment Research lowered Endologix from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Oppenheimer reaffirmed a “hold” rating on shares of Endologix in a research note on Wednesday, October 3rd. Piper Jaffray Companies dropped their price target on Endologix to $3.00 and set a “neutral” rating for the company in a research note on Wednesday, October 3rd. BTIG Research dropped their price target on Endologix to $4.00 and set a “buy” rating for the company in a research note on Thursday, August 23rd. Finally, BidaskClub lowered Endologix from a “hold” rating to a “sell” rating in a research note on Friday, August 17th.

In other Endologix news, CFO Vaseem Mahboob purchased 30,000 shares of Endologix stock in a transaction that occurred on Thursday, August 16th. The shares were bought at an average price of $2.43 per share, for a total transaction of $72,900.00. Following the acquisition, the chief financial officer now directly owns 146,812 shares in the company, valued at $356,753.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.90% of the stock is owned by insiders.



A number of large investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC increased its holdings in Endologix by 128.2% during the 2nd quarter. MetLife Investment Advisors LLC now owns 41,313 shares of the medical instruments supplier’s stock valued at $234,000 after purchasing an additional 23,210 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Endologix by 8.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 380,648 shares of the medical instruments supplier’s stock valued at $1,611,000 after purchasing an additional 30,585 shares during the period. C WorldWide Group Holding A S increased its holdings in Endologix by 22.3% during the 2nd quarter. C WorldWide Group Holding A S now owns 364,464 shares of the medical instruments supplier’s stock valued at $2,063,000 after purchasing an additional 66,486 shares during the period. Engineers Gate Manager LP purchased a new position in Endologix during the 2nd quarter valued at about $442,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Endologix by 14.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,431,962 shares of the medical instruments supplier’s stock worth $8,105,000 after acquiring an additional 175,970 shares during the period. Institutional investors own 94.05% of the company’s stock.

Shares of NASDAQ ELGX traded up $0.04 during mid-day trading on Friday, hitting $1.23. The company had a trading volume of 1,421,121 shares, compared to its average volume of 994,899. Endologix has a 1 year low of $1.09 and a 1 year high of $6.72. The company has a current ratio of 1.90, a quick ratio of 1.20 and a debt-to-equity ratio of 5.37.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The company had revenue of $44.70 million during the quarter, compared to analyst estimates of $44.43 million. Endologix had a negative return on equity of 69.06% and a negative net margin of 40.92%. The firm’s quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.10) earnings per share. As a group, sell-side analysts forecast that Endologix will post -0.86 earnings per share for the current fiscal year.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Featured Story: Call Option

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply